Aptos, California
United States
24
2025-03-20
The entities that hold a legal rights for patent applications filed by inventor Johnson Dave:
Dave Johnson from Aptos, US has applied for patents for these inventions. The list has both pending applications and granted patents:
Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
#2 | 2024-07-04BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
#3 | 2024-06-06Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#4 | 2022-03-24Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
#5 | 2021-12-30Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#6 | 2021-11-11BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
#7 | 2021-10-21Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
#8 | 2020-03-05Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#9 | 2019-12-19BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
#10 | 2019-11-28Therapeutic Combination of a PI3K Inhibitor and a BTK Inhibitor
#11 | 2019-10-17Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
#12 | 2019-09-26Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#13 | 2018-12-27BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
#14 | 2018-09-06Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor
#15 | 2018-09-06Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
#16 | 2018-07-26Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
#17 | 2017-09-21Therapeutic combination of PI3K inhibitor and a BTK inhibitor
#18 | 2017-08-24Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#19 | 2017-08-17BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
#20 | 2017-08-17Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
#21 | 2017-08-10Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
#22 | 2017-05-25Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
#23 | 2017-05-18Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
#24 | 2017-04-06Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
1841688 ⎘